Last reviewed · How we verify
Treatment E- Fexofenadine HCl 120mg
Treatment E- Fexofenadine HCl 120mg is a Small molecule drug developed by Sen-Jam Pharmaceutical. It is currently in Phase 1 development.
At a glance
| Generic name | Treatment E- Fexofenadine HCl 120mg |
|---|---|
| Sponsor | Sen-Jam Pharmaceutical |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of SJP-001 in Comparison With Fexofenadine and Naproxen Administered With Alcohol (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Treatment E- Fexofenadine HCl 120mg CI brief — competitive landscape report
- Treatment E- Fexofenadine HCl 120mg updates RSS · CI watch RSS
- Sen-Jam Pharmaceutical portfolio CI
Frequently asked questions about Treatment E- Fexofenadine HCl 120mg
What is Treatment E- Fexofenadine HCl 120mg?
Treatment E- Fexofenadine HCl 120mg is a Small molecule drug developed by Sen-Jam Pharmaceutical.
Who makes Treatment E- Fexofenadine HCl 120mg?
Treatment E- Fexofenadine HCl 120mg is developed by Sen-Jam Pharmaceutical (see full Sen-Jam Pharmaceutical pipeline at /company/sen-jam-pharmaceutical).
What development phase is Treatment E- Fexofenadine HCl 120mg in?
Treatment E- Fexofenadine HCl 120mg is in Phase 1.